All In Biotech

NDA 018877 · Watson Labs

Allopurinol

Allopurinol · Oral · Xanthine Oxidase Inhibitor

Last checked: Nov 20, 2026Latest source record: Apr 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Sep 28, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

209

51 Phase 3, 13 recruiting

FAERS reports

157,733

129,250 serious, 22,110 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 22, 2024.

INDICATIONS AND USAGE THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). Allopurinol is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 28, 1984 Original approval
1 products under this application
  • ALLOPURINOL · ALLOPURINOL 300MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Allopurinol" as an intervention, any sponsor and status, largest first.

All 209 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea8,831
  • fatigue8,385
  • dyspnoea8,016
  • nausea7,396
  • death6,985
  • acute kidney injury6,871
  • off label use6,805
  • pyrexia6,125
  • pneumonia5,754
  • asthenia5,712
  • anaemia5,511
  • drug ineffective5,239

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,482
20052,097
20062,078
20071,811
20082,226
20092,744
20103,358
20114,397
20125,349
20135,158
20145,525
20158,242
20169,189
20179,475
201812,939
201913,166
202012,834
202111,186
202210,728
20239,249
20248,953
20259,066
20266,469

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Feb 19, 2026

    Allopurinol, Tablet, 300 mg (NDC 0591-5544-05). Discontinuation of the manufacture of the drug

  • To Be Discontinued · updated Feb 19, 2026

    Allopurinol, Tablet, 300 mg (NDC 0591-5544-01). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Allopurinol (Allopurinol)

2024 spending

$96.3M

Beneficiaries

2,355,824

9,710,041 claims

Per beneficiary

$41

$0.13 per unit

View as table
YearSpending
2020$139,009,831
2021$135,197,968
2022$136,265,202
2023$136,919,385
2024$96,258,250

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 805 on PubMed

Sponsor: Watson Labs

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.